rawfin.tv
Leerink Initiates Avalo Therapeutics With Outperform Rating, $38 Price Target
MarketsstocksAI Generated

Leerink Initiates Avalo Therapeutics With Outperform Rating, $38 Price Target

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Leerink has begun coverage of Avalo Therapeutics Inc. (AVTX) with an Outperform rating, signaling a positive outlook for the stock. The firm set a price target of $38.00 per share.

AVTXAnalyst RatingBiotechnologyPrice Target

Related Articles

S&P 500 Heavyweights Face Earnings Test Amid Fed Meeting

S&P 500 Heavyweights Face Earnings Test Amid Fed Meeting

stocks
China Equities Lag US Stocks by Record 2.095 Valuation Ratio

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

stocks
S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks